Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting

• Samia Mourah ,

  * E-mail: samia.mourah@sls.aphp.fr

  Affiliations Department of Pharmacology-Genetics, AP-HP, Saint-Louis Hospital, Paris, France, INSERM UMRS 976 Paris, F-75010, France

  ⨯
• Marc G. Denis,

  Affiliation Department of Biochemistry, Nantes University Hospital, Nantes, France

  ⨯
• Fabienne Escande Narducci,

  Affiliation Department of Molecular Biology and Biochemistry, Lille Regional University Hospital, Lille, France

  ⨯
• Jérôme Solassol,

  Affiliation Department of Biology—Pathology, Montpellier University Hospital, Montpellier, France

  ⨯
• Jean-Louis Merlin,

  Affiliation Department of Tumor Biology, Alexis Vautrin Center, Vandoeuvre les Nancy, France

  ⨯
• Jean-Christophe Sabourin,

  Affiliation Department of Pathology—Cytopathology, Rouen University Hospital, Rouen, France

  ⨯
• Jean-Yves Scoazec,

  Affiliations Laboratory of Pathology and Cytopathology, Edouard Herriot Hospital, Lyon, France, Department of Biology and Pathology, Gustave Roussy Hospital, Villejuif, France

  ⨯
• L’Houcine Ouafik,

  Affiliation Department of Cancer Biology, Marseille Nord University Hospital, Marseille, France

  ⨯
• Jean-François Emile,

  Affiliation Department of Pathology, Ambroise Paré Hospital, Boulogne-Billancourt, France

  ⨯
• Remy Heller,

  Affiliation Department of Microbiology and Molecular Biology, Colmar hospital, Colmar, France

  ⨯
• Claude Souvignet,

  Affiliation Roche, Boulogne-Billancourt, France

  ⨯
• Loïc Bergougnoux,

  Affiliation Roche, Boulogne-Billancourt, France

  ⨯
• Jean-Philippe Merlio

  Affiliation Department of Tumor Biology, Bordeaux University Hospital, Bordeaux, France

  ⨯